Table 2 Pharmacokinetic and toxicity properties for PubChem-162-396-453, PubChem-162-396-449, PubChem-162-396-448, and nirmatrelvir.

From: Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 Mpro inhibitors

PubChem Code

Absorption (A)

Distribution (D)

Metabolism (M)

Excretion (E)

Toxicity (T)

Caco2 permeability

Skin permeability (log Kp)

Blood Brain Barrier (BBB)

CNS permeability

(Log PS)

CYP3A4 substrate

CYP3A4

inhibitor

Total Clearance

AMES toxicity

skin sensitization

Nirmatrelvir

0.155

−3.178

−0.949

−3.208

Yes

No

0.26

Yes

No

PubChem-162-396-453

0.206

−3.142

−1.006

−3.389

Yes

No

0.424

No

No

PubChem-162-396-449

0.437

−2.893

−1.288

−4.187

Yes

No

0.387

No

No

PubChem-162-396-448

0.449

−2.944

−1.201

−4.131

Yes

No

0.42

No

No